Press Releases
GI Dynamics Announces Extension of Maturity Date of US $5M Convertible Note with Crystal Amber
BOSTON and SYDNEY – 1 July 2019 – GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has reached an agreement with Crystal Amber Fund Limited (Crystal Amber) to extend the Maturity Date...
read moreGI Dynamics Announces Access to 2019 Annual Meeting of Stockholders and Corporate Update
BOSTON and SYDNEY — 25 June 2019 — GI Dynamics®, Inc. (ASX: GID) (the Company) will hold its 2019 Annual Meeting of Stockholders on 30 June 2019 at 7:00 am United States Eastern Daylight Time, (which is 30 June 2019 at 9:00 pm Australian Eastern Standard Time), at the offices of Mintz, Levin,...
read moreNew Scientific Advisory Board Member to Focus on Treatment of Liver Disease
BOSTON and SYDNEY — 18 June 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the addition of a new member to its Scientific Advisory Board (SAB). GI Dynamics welcomes Steven Opal,...
read moreEndoBarrier Sleep Apnea Study Shows Significant Improvements Sustained Post Explant
BOSTON and SYDNEY — 14 June 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data presented at the American Diabetes Association’s 79th Scientific Sessions in San Francisco,...
read moreGI Dynamics Confirms First Two Clinical Study Sites Contracted for US Pivotal Trial of EndoBarrier
BOSTON and SYDNEY — 13 June 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the execution of contracts with the first two clinical sites of the STEP-1 (single therapy euglycemic...
read moreEndoBarrier Data to be Presented at the American Diabetes Association’s 79th Scientific Sessions
BOSTON and SYDNEY — 6 June 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that EndoBarrier data will be presented at the American Diabetes Association’s 79th Scientific Sessions,...
read moreGI Dynamics 2019 Annual Meeting of Stockholders – Update
BOSTON and SYDNEY — 4 June 2019 — GI Dynamics® Inc. (ASX:GID) (Company or GI Dynamics), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to provide the following update regarding the GI Dynamics 2019 Annual Meeting of Stockholders...
read moreGI Dynamics Announces US $3M Convertible Note and Warrant Financing from Crystal Amber Fund Limited
BOSTON and SYDNEY — 9 May 2019 — GI Dynamics® Inc. (ASX:GID) (Company or GI Dynamics), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has agreed to the terms of a US $3,000,000 convertible note and warrant...
read moreGI Dynamics Announces Extension of Maturity Date of US $5M Convertible Note with Crystal Amber
BOSTON and SYDNEY – 1 May 2019 – GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has reached an agreement with Crystal Amber Fund Limited (Crystal Amber) to extend the Maturity Date...
read moreGI Dynamics Announces New Scientific Advisory Board Member
BOSTON and SYDNEY — 9 April 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the addition of a new member to its Scientific Advisory Board (SAB). GI Dynamics welcomes Judith Korner,...
read more